BACKGROUND: Multiple health problems have been reported in survivors of Ebola virus disease (EVD). Attribution of these problems to the disease without a control group for analysis is difficult. METHODS: We enrolled a cohort of EVD survivors and their close contacts and prospectively collected data on symptoms, physical examination findings, and laboratory results. A subset of participants underwent ophthalmologic examinations. Persistence of Ebola virus (EBOV) RNA in semen samples from survivors was determined. RESULTS: A total of 966 EBOV antibody-positive survivors and 2350 antibody-negative close contacts (controls) were enrolled, and 90% of these participants were followed for 12 months. At enrollment (median time to baseline visit, 358 days after symptom onset), six symptoms were reported significantly more often among survivors than among controls: urinary frequency (14.7% vs. 3.4%), headache (47.6% vs. 35.6%), fatigue (18.4% vs. 6.3%), muscle pain (23.1% vs. 10.1%), memory loss (29.2% vs. 4.8%), and joint pain (47.5% vs. 17.5%). On examination, more survivors than controls had abnormal abdominal, chest, neurologic, and musculoskeletal findings and uveitis. Other than uveitis (prevalence at enrollment, 26.4% vs. 12.1%; at year 1, 33.3% vs. 15.4%), the prevalence of these conditions declined during follow-up in both groups. The incidence of most symptoms, neurologic findings, and uveitis was greater among survivors than among controls. EBOV RNA was detected in semen samples from 30% of the survivors tested, with a maximum time from illness to detection of 40 months. CONCLUSIONS: A relatively high burden of symptoms was seen in all participants, but certain symptoms and examination findings were more common among survivors. With the exception of uveitis, these conditions declined in prevalence during follow-up in both groups. Viral RNA in semen persisted for a maximum of 40 months. (Funded by the National Institute of Allergy and Infectious Diseases and the National Eye Institute; PREVAIL III ClinicalTrials.gov number, NCT02431923.).
BACKGROUND: Multiple health problems have been reported in survivors of Ebola virus disease (EVD). Attribution of these problems to the disease without a control group for analysis is difficult. METHODS: We enrolled a cohort of EVD survivors and their close contacts and prospectively collected data on symptoms, physical examination findings, and laboratory results. A subset of participants underwent ophthalmologic examinations. Persistence of Ebola virus (EBOV) RNA in semen samples from survivors was determined. RESULTS: A total of 966 EBOV antibody-positive survivors and 2350 antibody-negative close contacts (controls) were enrolled, and 90% of these participants were followed for 12 months. At enrollment (median time to baseline visit, 358 days after symptom onset), six symptoms were reported significantly more often among survivors than among controls: urinary frequency (14.7% vs. 3.4%), headache (47.6% vs. 35.6%), fatigue (18.4% vs. 6.3%), muscle pain (23.1% vs. 10.1%), memory loss (29.2% vs. 4.8%), and joint pain (47.5% vs. 17.5%). On examination, more survivors than controls had abnormal abdominal, chest, neurologic, and musculoskeletal findings and uveitis. Other than uveitis (prevalence at enrollment, 26.4% vs. 12.1%; at year 1, 33.3% vs. 15.4%), the prevalence of these conditions declined during follow-up in both groups. The incidence of most symptoms, neurologic findings, and uveitis was greater among survivors than among controls. EBOV RNA was detected in semen samples from 30% of the survivors tested, with a maximum time from illness to detection of 40 months. CONCLUSIONS: A relatively high burden of symptoms was seen in all participants, but certain symptoms and examination findings were more common among survivors. With the exception of uveitis, these conditions declined in prevalence during follow-up in both groups. Viral RNA in semen persisted for a maximum of 40 months. (Funded by the National Institute of Allergy and Infectious Diseases and the National Eye Institute; PREVAIL III ClinicalTrials.gov number, NCT02431923.).
Authors: Paul J Carson; Patrick Konewko; Kimberly S Wold; Paul Mariani; Sunil Goli; Paula Bergloff; Ross D Crosby Journal: Clin Infect Dis Date: 2006-08-10 Impact factor: 9.079
Authors: Suzanne E Mate; Jeffrey R Kugelman; Tolbert G Nyenswah; Jason T Ladner; Michael R Wiley; Thierry Cordier-Lassalle; Athalia Christie; Gary P Schroth; Stephen M Gross; Gloria J Davies-Wayne; Shivam A Shinde; Ratnesh Murugan; Sonpon B Sieh; Moses Badio; Lawrence Fakoli; Fahn Taweh; Emmie de Wit; Neeltje van Doremalen; Vincent J Munster; James Pettitt; Karla Prieto; Ben W Humrighouse; Ute Ströher; Joseph W DiClaro; Lisa E Hensley; Randal J Schoepp; David Safronetz; Joseph Fair; Jens H Kuhn; David J Blackley; A Scott Laney; Desmond E Williams; Terrence Lo; Alex Gasasira; Stuart T Nichol; Pierre Formenty; Francis N Kateh; Kevin M De Cock; Fatorma Bolay; Mariano Sanchez-Lockhart; Gustavo Palacios Journal: N Engl J Med Date: 2015-10-14 Impact factor: 91.245
Authors: Ian Hickie; Tracey Davenport; Denis Wakefield; Ute Vollmer-Conna; Barbara Cameron; Suzanne D Vernon; William C Reeves; Andrew Lloyd Journal: BMJ Date: 2006-09-01
Authors: Danielle V Clark; Hannah Kibuuka; Monica Millard; Salim Wakabi; Luswa Lukwago; Alison Taylor; Michael A Eller; Leigh Anne Eller; Nelson L Michael; Anna N Honko; Gene G Olinger; Randal J Schoepp; Matthew J Hepburn; Lisa E Hensley; Merlin L Robb Journal: Lancet Infect Dis Date: 2015-04-21 Impact factor: 25.071
Authors: Kamilla D Lettinga; Annelies Verbon; Pythia T Nieuwkerk; Rene E Jonkers; Berthold P R Gersons; Jan M Prins; Peter Speelman Journal: Clin Infect Dis Date: 2002-06-07 Impact factor: 9.079
Authors: Gibrilla F Deen; Nathalie Broutet; Wenbo Xu; Barbara Knust; Foday R Sesay; Suzanna L R McDonald; Elizabeth Ervin; Jaclyn E Marrinan; Philippe Gaillard; Ndema Habib; Hongtu Liu; William Liu; Anna E Thorson; Francis Yamba; Thomas A Massaquoi; Faustin James; Archchun Ariyarajah; Christine Ross; Kyle Bernstein; Antoine Coursier; John Klena; Marylin Carino; Alie H Wurie; Yong Zhang; Marion S Dumbuya; Neetu Abad; Baimba Idriss; Teodora Wi; Sarah D Bennett; Tina Davies; Faiqa K Ebrahim; Elissa Meites; Dhamari Naidoo; Samuel J Smith; Patricia Ongpin; Tasneem Malik; Anshu Banerjee; Bobbie R Erickson; Yongjian Liu; Yang Liu; Ke Xu; Aaron Brault; Kara N Durski; Jörn Winter; Tara Sealy; Stuart T Nichol; Margaret Lamunu; James Bangura; Sihem Landoulsi; Amara Jambai; Oliver Morgan; Guizhen Wu; Mifang Liang; Qiudong Su; Yu Lan; Yanzhe Hao; Pierre Formenty; Ute Ströher; Foday Sahr Journal: N Engl J Med Date: 2015-10-14 Impact factor: 91.245
Authors: John G Mattia; Mathew J Vandy; Joyce C Chang; Devin E Platt; Kerry Dierberg; Daniel G Bausch; Tim Brooks; Sampha Conteh; Ian Crozier; Robert A Fowler; Amadu P Kamara; Cindy Kang; Srividya Mahadevan; Yealie Mansaray; Lauren Marcell; Gillian McKay; Tim O'Dempsey; Victoria Parris; Ruxandra Pinto; Audrey Rangel; Alex P Salam; Jessica Shantha; Vanessa Wolfman; Steven Yeh; Adrienne K Chan; Sharmistha Mishra Journal: Lancet Infect Dis Date: 2015-12-23 Impact factor: 25.071
Authors: Sam Tozay; William A Fischer; David A Wohl; Kayla Kilpatrick; Fei Zou; Edwina Reeves; Korto Pewu; Jean DeMarco; Amy James Loftis; Katie King; Donald Grant; John Schieffelin; Galakpai Gorvego; Henrietta Johnson; Tonia Conneh; Gerald Williams; Julie A E Nelson; David Hoover; Darrius McMillian; Carson Merenbloom; Darrell Hawks; Karine Dube; Jerry Brown Journal: Clin Infect Dis Date: 2020-10-23 Impact factor: 9.079
Authors: Surender Khurana; Supriya Ravichandran; Megan Hahn; Elizabeth M Coyle; Spencer W Stonier; Samantha E Zak; Jason Kindrachuk; Richard T Davey; John M Dye; Daniel S Chertow Journal: Cell Host Microbe Date: 2020-02-12 Impact factor: 21.023
Authors: Stephanie M LaVergne; Saori Sakabe; Lansana Kanneh; Mambu Momoh; Foday Al-Hassan; Mohamed Yilah; Augustine Goba; John Demby Sandi; Michael Gbakie; Beatrice Cubitt; Matthew Boisen; Jessica M Mayeux; Ashley Smira; Kayla Shore; Iris Bica; K Michael Pollard; Juan Carlos de la Torre; Luis M Branco; Robert F Garry; Donald S Grant; John S Schieffelin; Michael B A Oldstone; Brian M Sullivan Journal: J Infect Dis Date: 2020-10-01 Impact factor: 5.226
Authors: Elizabeth S Higgs; Dehkontee Gayedyu-Dennis; William A Fischer Ii; Martha Nason; Cavan Reilly; Abdoul Habib Beavogui; Jamila Aboulhab; Jacqueline Nordwall; Princess Lobbo; Ian Wachekwa; Huyen Cao; Tomas Cihlar; Lisa Hensley; H Clifford Lane Journal: Clin Infect Dis Date: 2021-11-16 Impact factor: 9.079
Authors: Shevin T Jacob; Ian Crozier; William A Fischer; Angela Hewlett; Colleen S Kraft; Marc-Antoine de La Vega; Moses J Soka; Victoria Wahl; Anthony Griffiths; Laura Bollinger; Jens H Kuhn Journal: Nat Rev Dis Primers Date: 2020-02-20 Impact factor: 52.329
Authors: Thiago A Teixeira; Yasmin C Oliveira; Felipe S Bernardes; Esper G Kallas; Amaro N Duarte-Neto; Sandro C Esteves; Joël R Drevet; Jorge Hallak Journal: Asian J Androl Date: 2021 Jul-Aug Impact factor: 3.285